NCT01488539

Brief Summary

Researchers hope to learn whether a flexibly applied cognitive behavioral treatment for Post-Traumatic Stress Disorder (PTSD) is more effective than the psychotherapy usually provided in the clinic (called Treatment as Usual or TAU). Primary Hypothesis: STAIR/NT will be superior to TAU in improving PTSD symptoms at 28, 36 and 48 weeks post-randomization

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
210

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jan 2012

Longer than P75 for not_applicable

Geographic Reach
1 country

5 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 2, 2011

Completed
6 days until next milestone

First Posted

Study publicly available on registry

December 8, 2011

Completed
24 days until next milestone

Study Start

First participant enrolled

January 1, 2012

Completed
4.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2016

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2017

Completed
Last Updated

August 18, 2023

Status Verified

August 1, 2023

Enrollment Period

4.3 years

First QC Date

December 2, 2011

Last Update Submit

August 15, 2023

Conditions

Keywords

Stress Disorders, Post-TraumaticPTSDAdult Survivors of Child AbuseWomenInterpersonal violencepsychological trauma

Outcome Measures

Primary Outcomes (2)

  • Clinician Assessed PTSD Symptom Severity

    Clinician Adminstered PTSD Scale for DSM-5 (CAPS-5) includes 20 items rated on a 5 point scale from 0 to 4. Possible total scores range from 0 to 80, with higher scores indicating more severe PTSD.

    Baseline, 28, 36, 48 weeks

  • PTSD Diagnosis

    Clinician Adminstered PTSD Scale for DSM-5 (CAPS-5) assess the presence of PTSD diagnosis following the requirements indicated by DSM-5. These include the presence of 5 symtpom clusters that include re-experiencing symptoms, avoidance symptoms, alterations in mood and cognitions and hyperarousal.

    Baseline, 28, 36, 48 weeks

Secondary Outcomes (3)

  • Emotion Regulation Problems

    Baseline, 12, 28, 36, 48 weeks

  • Interpersonal problems

    Baseline, 12, 28, 36, 48 weeks

  • Psychosocial Functioning

    Baseline, 28, 36, 48 weeks

Study Arms (2)

STAIR/NT

EXPERIMENTAL

Patients will receive STAIR/NT treatment

Behavioral: STAIR/NT treatment

Treatment as Usual (TAU)

OTHER

Patients will receive Treatment as Usual (TAU)

Behavioral: Treatment as Usual (TAU)

Interventions

STAIR/NT is a two module, sequential treatment in which the first module emphasizes present-focused skills training in affective an interpersonal regulation (STAIR) for day-to-day life difficulties and the second module incorporates past-focused work on the processing of the trauma, using narrative therapy (NT). STAIR/NT is a cognitive behavioral treatment that can be flexibly applied allowing treatment tailored to the needs of the individual patient; may be as brief as 16 sessions and as long as 24.

STAIR/NT

The Treatment as Usual intervention content varies from site to site and involve some combination of psychotherapy and pharmacotherapy. Treatment duration varies across sites and ranges from 30 to 45 sessions.

Treatment as Usual (TAU)

Eligibility Criteria

Age18 Years - 65 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • A primary diagnosis of PTSD according to DSM-IV criteria with a CAPS score no lower than 40 (cf Weathers, Keane, \& Davidson, 2001)
  • PTSD symptoms that are a result of interpersonal violence
  • at least one clear trauma memory
  • Current age between 18 and 65
  • If obtaining other (medication or psychosocial) treatment, must have completed at least a 3 month course of the treatment

You may not qualify if:

  • Substance dependence and severe substance abuse disorders, current psychotic symptoms, unmedicated mania or bipolar disorder
  • prominent current suicidal or homicidal ideation (a plan or intent versus a wish) or a suicide attempt within the past three months
  • self-injurious behaviors in the last three months requiring medical attention
  • Cognitive impairment indicated by chart diagnoses or observable cognitive difficulties
  • Current involvement in a violent relationship defined as more than casual contact (e.g. dating or living with an abusive partner)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (5)

University of Connecticut Health Center

Farmington, Connecticut, 06030, United States

Location

Georgetown University School of Medicine

Washington D.C., District of Columbia, 20057, United States

Location

Grady Health System

Atlanta, Georgia, 30303, United States

Location

Cambridge Health Alliance

Cambridge, Massachusetts, 02139, United States

Location

New York University- Bellevue

New York, New York, 10016, United States

Location

Related Publications (1)

  • Cloitre M, Henn-Haase C, Herman JL, Jackson C, Kaslow N, Klein C, Mendelsohn M, Petkova E. A multi-site single-blind clinical study to compare the effects of STAIR Narrative Therapy to treatment as usual among women with PTSD in public sector mental health settings: study protocol for a randomized controlled trial. Trials. 2014 May 29;15:197. doi: 10.1186/1745-6215-15-197.

    PMID: 24886235BACKGROUND

MeSH Terms

Conditions

Stress Disorders, Post-TraumaticPsychological Trauma

Interventions

Therapeutics

Condition Hierarchy (Ancestors)

Stress Disorders, TraumaticTrauma and Stressor Related DisordersMental Disorders

Study Officials

  • Marylene Cloitre, PhD

    VA Palo Alto Health Care System

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Research Health Science Specialist

Study Record Dates

First Submitted

December 2, 2011

First Posted

December 8, 2011

Study Start

January 1, 2012

Primary Completion

April 1, 2016

Study Completion

April 1, 2017

Last Updated

August 18, 2023

Record last verified: 2023-08

Locations